and apolipoprotein B ≤110 mg/dL were randomly assigned to one of four treatment groups: rosuvastatin 10-40 mg, ER niacin 0.5-2 g, rosuvastatin 40 mg plus ER niacin 0.5-1 g, or rosuvastatin 10 mg ...

Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH), which is expected to begin in 2H 2025 Phase 1 trial in healthy volunteers showed MBX 1416 was generall ...

In the MAD cohort, MBX 1416 appeared to increase GLP-1 within 60 minutes of a mixed meal tolerance test, suggesting a ...

10-mg rosuvastatin, 20- to 40-mg simvastatin, 40-mg pravastatin, 40-mg lovastatin, and so forth. Lipid-lowering therapy has been shown to be as effective in adults over age 70 as in younger people.

10–15 However, all of these studies have not evaluated ... evaluating the efficacy and safety of high-intensity statin therapy (atorvastatin 80 mg or rosuvastatin 20/40 mg) in patients with CKD were ...

Medicinal products that are substrates of breast cancer resistance protein (BCRP) Co-administration of a single 10 mg dose of rosuvastatin (a BCRP substrate) with a single 5 mg dose of FRUZAQLA ...

The group also lowered its suggested minimum age for drug treatment from 10 to 8. The findings from studies ... the blood—along the lines of over 500 mg/dL, leading to artery damage and possibly ...

This study defined moderate lipid‐lowering therapy as therapy with a theoretical reduction of >40% in LDL‐C levels (eg, atorvastatin 20 mg, rosuvastatin 10 mg, and pravastatin 40 mg), according to the ...

Medicinal products that are substrates of breast cancer resistance protein (BCRP) Co-administration of a single 10 mg dose of rosuvastatin (a BCRP substrate) with a single 5 mg dose of FRUZAQLA ...

This corresponds to 20–40 mg for rosuvastatin and 40–80 mg for atorvastatin or simvastatin ... (2009) 171:39–41. doi: 10.1111/j.0954-6820.1962.tb04165.x ...